ICON

ICON, established in 1990, is a leading global provider of drug and device development and commercialization services. Operating within the Business Services sector, ICON serves pharmaceutical, biotechnology, medical device, and government and public health organizations worldwide. The company's comprehensive offerings span the entire lifecycle of product development, from early-stage clinical research to late-stage commercialization support, including clinical trials, healthcare intelligence, and strategic development services.

With a significant global footprint, ICON employs over 10,000 professionals across 18 locations. This extensive network enables the company to deliver specialized services such as clinical consulting, contract research, and development management. ICON's operational excellence is supported by a dedicated team focused on innovation and quality in life science language services, medical imaging, and laboratory services. Learn about ICON's global headquarters for detailed geographic presence and operational reach. Meet ICON's team to understand the expertise driving their global initiatives.

Generating substantial revenue, ICON reported $8.1B in earnings, underscoring its market leadership and financial strength in the contract research organization (CRO) space. The company's strategic development and commercialization services are critical for bringing new drugs and medical devices to market efficiently and compliantly. ICON's commitment to advancing healthcare solutions is evident in its broad portfolio of services, positioning it as a key partner for organizations navigating complex regulatory and scientific landscapes. Explore financial highlights for a deeper dive into their fiscal performance and market impact.